PREEMPTIVE RITUXIMAB TO PREVENT RECURRENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS POST-TRANSPLANT

$3,589,576FY2018Defense Health AgencyDOD

Regents Of The University Of Minnesota

Investigators